Inflammatory Disease
B-cell therapies, mycophenolate worsen COVID-19 vaccine response in inflammatory disease
Patients with chronic inflammatory disease on immunosuppressants, especially B-cell depleting agents, mycophenolate and glucocorticoids, exhibited poor antibody responses to the mRNA vaccine for COVID-19, according to a presenter here.
FDA approves Cyltezo as first interchangeable biosimilar for inflammatory disease
The FDA has designated Cyltezo the first approved interchangeable biosimilar to treat certain inflammatory diseases, allowing pharmacists to substitute it for Humira without the need for the prescriber to alter the prescription.
Hidradenitis suppurativa treatment should be 'layered,' address psychosocial impacts
Providers should avoid monotherapy when treating hidradenitis suppurativa, and instead use a “layered and rotated” approach that also addresses the isolating psychosocial aspects of the disease, noted a speaker here.
MI, systemic inflammatory disease elevate mortality risk in young adults
Patients aged 50 years or younger who had an MI and have autoimmune systemic inflammatory diseases had elevated rates of long-term all-cause mortality, according to a study published in the European Journal of Preventive Cardiology.
Study of COVID-19 provides 'unparalleled' chance to advance autoimmunity knowledge
Studies examining the immunopathogenesis of COVID-19 and its link to immune system dysregulation are providing an “unparalleled opportunity” to learn more about autoimmunity, according to a review published in Pathogens and Immunity.
Speaker clarifies multisystem inflammatory syndrome in children with COVID-19
IV immunoglobulin plus methylprednisolone linked to better fever course in MIS-C
Treatment with IV immunoglobulin plus methylprednisolone resulted in a more favorable fever course — and fewer complications — in children with COVID-19-related multisystem inflammatory syndrome than IV immunoglobulins alone.
Patients with inflammatory rheumatic disease more likely to be hospitalized with COVID-19
Patients with inflammatory rheumatic disease exhibited a higher incidence of COVID-19 hospitalization than the general population, and those with rheumatoid arthritis are at a greater risk for severe outcomes, according to data.
ACR recommends 'stepwise approach' to immunomodulatory therapy in MIS-C linked to COVID-19
A stepwise approach to immunomodulatory drugs is recommended for children with multisystem inflammatory syndrome linked to COVID-19, with IVIG and glucocorticoids as first-tier agents, noted updated American College of Rheumatology guidance.